Oncocyte (NASDAQ:IMDX) Major Shareholder Broadwood Partners, L.P. Acquires 280,381 Shares

Oncocyte Corp (NASDAQ:IMDX) major shareholder Broadwood Partners, L.P. acquired 280,381 shares of Oncocyte stock in a transaction dated Thursday, April 23rd. The shares were bought at an average price of $3.50 per share, for a total transaction of $981,333.50. Following the transaction, the insider owned 12,395,081 shares of the company’s stock, valued at approximately $43,382,783.50. The trade was a 2.31% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, April 27th, Broadwood Partners, L.P. bought 250,923 shares of Oncocyte stock. The shares were bought at an average price of $3.64 per share, with a total value of $913,359.72.
• On Friday, April 24th, Broadwood Partners, L.P. purchased 38,880 shares of Oncocyte stock. The stock was bought at an average price of $3.53 per share, for a total transaction of $137,246.40.
• On Monday, April 20th, Broadwood Partners, L.P. purchased 40,690 shares of Oncocyte stock. The stock was bought at an average price of $3.88 per share, for a total transaction of $157,877.20.
• On Friday, April 17th, Broadwood Partners, L.P. purchased 40,114 shares of Oncocyte stock. The stock was bought at an average price of $3.57 per share, for a total transaction of $143,206.98.
• On Thursday, April 16th, Broadwood Partners, L.P. purchased 102,057 shares of Oncocyte stock. The stock was bought at an average price of $3.45 per share, for a total transaction of $352,096.65.
• On Tuesday, February 10th, Broadwood Partners, L.P. acquired 521,739 shares of Oncocyte stock. The shares were bought at an average cost of $5.75 per share, with a total value of $2,999,999.25.

Oncocyte Trading Up 2.1%

Shares of Oncocyte stock opened at $3.84 on Tuesday. Oncocyte Corp has a twelve month low of $2.33 and a twelve month high of $8.51. The firm’s 50-day moving average price is $4.34. The stock has a market capitalization of $123.53 million, a price-to-earnings ratio of -2.37 and a beta of 1.52.

Oncocyte (NASDAQ:IMDX) last posted its earnings results on Thursday, March 26th. The company reported ($0.27) EPS for the quarter. The company had revenue of $1.14 million during the quarter.

Analyst Ratings Changes

IMDX has been the topic of a number of recent research reports. Wall Street Zen downgraded shares of Oncocyte from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Oncocyte in a report on Friday, March 27th. Finally, Lake Street Capital upped their target price on shares of Oncocyte from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $12.00.

Oncocyte Company Profile

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.